Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia
Status:
Recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to proof the safety and efficacy of a single bilateral
subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked
achromatopsia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
STZ eyetrial
Collaborators:
Ludwig-Maximilians - University of Munich University Hospital Tuebingen